Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT + Cadonilimab + Lenvatinib for Unresectable HCC with PVTT
NCT06040177Phase 2Unknown
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Feb 2023
- Primary completion
- Feb 2023
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in hepatocellular carcinoma (HCC), sponsored by The First Affiliated Hospital of Guangxi Medical University. Status: unknown.
02
Drugs
cadonilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06040177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06040177.